Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2224003 | 1.00 | DPP4 (0.33) | DPP4DPP7SCN9ASLC18A3ALDH1A1 | |
| SCHEMBL2221226 | 1.00 | DPP4 (0.33) | DPP4DPP7SCN9ASLC18A3ALDH1A1 | |
| SCHEMBL1444883 | 1.00 | DPP4 (0.33) | DPP4DPP7SCN9ASLC18A3ALDH1A1 | |
| SCHEMBL29089569 | 1.00 | DPP4 (0.33) | DPP4DPP7SCN9ASLC18A3ALDH1A1 | |
| SCHEMBL2221215 | 1.00 | DPP4 (0.33) | DPP4DPP7SCN9ASLC18A3ALDH1A1 | |
| SCHEMBL288363 | 1.00 | DPP4 (0.33) | DPP4DPP7SCN9ASLC18A3ALDH1A1 | |
| SCHEMBL1964520 | 0.85 | L3MBTL3 (0.31) | ALDH1A1 | |
| SCHEMBL22467822 | 0.83 | SCN9A (0.32) | DPP4DPP7SCN9ASLC18A3ALDH1A1 | |
| SCHEMBL20973259 | 0.83 | SCN9A (0.32) | DPP4DPP7SCN9ASLC18A3ALDH1A1 | |
| SCHEMBL17801583 | 0.83 | SCN9A (0.32) | DPP4DPP7SCN9ASLC18A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137743-A1 | SUBSTITUTED IMIDAZO-BASED COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 | CELGENE CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-02 | — | — | US | disclosed |
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| WO-2024059169-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3558310-B1 | HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023180388-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023147594-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-4212515-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230063457-A1 | DNA-PK INHIBITING COMPOUNDS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-03-02 | — | — | US | disclosed |
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-03-05 | — | — | US | disclosed |
| WO-2015031613-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-03-05 | — | — | WO | disclosed |
| EP-2833889-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | Rigel Pharmaceuticals, Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| EP-2731944-A1 | GPR 119 MODULATORS | Pfizer Inc (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20130331374-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2013-12-12 | — | — | US | disclosed |
| WO-2013152198-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013011402-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | DPP4 1611/4885DPP7 1191/4885SCN9A 4739/4885 |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DPP4 308/4885DPP7 221/4885SCN9A 4703/4885 |
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | DPP4 620/4885DPP7 2477/4885SCN9A 4397/4885 |
| US-20130331374-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | DPP4 2085/4885DPP7 1085/4885SCN9A 4296/4885 |
| US-20230063457-A1 | DNA-PK INHIBITING COMPOUNDS | DCK, POLK, ERCC2 | DPP4 2750/4885DPP7 1646/4885SCN9A 4077/4885 |
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | ERBB2, ERBB3, AADAC | DPP4 2833/4885DPP7 1619/4885SCN9A 4715/4885 |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP11B2, SDHA, CYP3A43 | DPP4 1460/4885DPP7 1530/4885SCN9A 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.